Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.58 |
| ▸ | FABP1 | P07148 | 7/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003900 | 0.94 | NR1H4 (0.53) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL2006099 | 0.94 | NR1H4 (0.53) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL19900884 | 0.91 | NR1H4 (0.51) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL19899937 | 0.91 | NR1H4 (0.51) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL22790391 | 0.88 | NR1H4 (0.51) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL12168747 | 0.87 | NR1H4 (0.55) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL12168749 | 0.87 | NR1H4 (0.55) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL2004979 | 0.86 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL21161321 | 0.86 | NR1H4 (0.54) | NR1H4FABP1FABP4HSD17B13 | |
| SCHEMBL19230799 | 0.86 | NR1H4 (0.54) | NR1H4FABP1FABP4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486259-B2 | FXR agonist having pyrazine structure, and preparation method and use | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-114656460-B | Novel pyrazine FXR agonist, preparation method and application | 江苏天士力帝益药业有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-3246070-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING AZOLES | GILEAD SCIENCES INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| EP-2079307-A2 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | NR1H4 65/4885FABP1 132/4885FABP4 619/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | NR1H4 1/4885FABP1 54/4885FABP4 902/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885FABP1 45/4885FABP4 331/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885FABP1 63/4885FABP4 350/4885 |
| US-12486259-B2 | FXR agonist having pyrazine structure, and preparation method and use | FXR1, NR1H4, SLC10A1 | NR1H4 2/4885FABP1 19/4885FABP4 227/4885 |
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, FXR2 | NR1H4 1/4885FABP1 8/4885FABP4 97/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885FABP1 143/4885FABP4 725/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | NR1H4 1/4885FABP1 54/4885FABP4 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.